Skin compatibility of cyclodextrins and their derivatives: a comparative assessment using a corneoxenometry bioassay. by Piel, Géraldine et al.
Research paper
Skin compatibility of cyclodextrins and their derivatives:
a comparative assessment using a corneoxenometry bioassay
G. Piela,*, S. Moutardb, E. Uhodac, F. Pilardd, G.E. Pie´rardc,
B. Perlyb, L. Delattrea, B. Evrarda
aLaboratory of Pharmaceutical Technology, Department of Pharmacy, University of Lie`ge, Lie`ge, Belgium
bLaboratory of Molecular Chemistry, Gif-sur-Yvette, France
cDepartment of Dermatopathology, University Hospital, Lie`ge, Belgium
dLaboratory of Glucides, University of Amiens, Amiens, France
Received 22 September 2003; accepted in revised form 15 December 2003
Abstract
Few studies have been performed to assess the risk of skin damage by cyclodextrins (CD) and they have yielded contradictory results. The
present study was conducted using the corneoxenometry bioassay on human stratum corneum to compare the skin compatibility of CD
currently used in pharmaceutical preparations (bCD, gCD, Rameb, Dimeb, Trimeb, HP-bCD and HP-gCD) and that of new amphiphilic CD
derivatives, namely, the phospholipidyl-CD (DMPE-Dimeb and DMPE-Trimeb). All the tested CD were well tolerated by the stratum
corneum at a concentration of 5%. However, inter-individual reactivity was larger for DMPE-Dimeb, suggesting a more aggressive trend for
this compound. Cutaneous Index of Mildness values obtained confirm that Dimeb is able to extract some skin components and shows that
DMPE-Dimeb performs similarly.
q 2004 Elsevier B.V. All rights reserved.
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1. Introduction
For more than 20 years, cyclodextrins (CD) have
attracted interest owing to their possible applications in a
wide range of fields from fundamental research to industry.
Their practical use mainly arose from the capability of their
inclusion complexes to modify the chemical reactivity and
physical characteristics of the guest molecules. Many
chemically modified CD have been synthesized in order to
improve or modify some of their properties. Amphiphilic
CD are especially capable of forming by themselves or in
association with other amphiphiles or guest molecules,
stable supramolecular assemblies well recognized as
efficient drug carriers, such as micelles, vesicles or nano-
spheres. It has been also shown that they can be inserted
through their hydrophobic part into lipidic systems such as
liposomes, leaving the CD cavities outside and available to
include active guests. These supramolecular assemblies
represent new promising vectors since they combine the size
specificity of CD and the properties of organized bilayers as
molecular transporters [1].
With this scope in mind, amphiphilic CDs carrying a
phospholipidyl chain (the dimyristoylphosphatidylethano-
lamine, DMPE), the DMPE-dimethyl-bCD (DMPE-Dimeb)
and the DMPE-trimethyl-bCD (DMPE-Trimeb), have been
synthesized to mimic, as closely as possible, natural
membranes. The novel glyco-conjugates have been fully
characterized for dermatological delivery of xenobiotics
with low aqueous solubility (Fig. 1).
Many articles describe the use of CD in dermatological
preparations, but few studies describe their compatibility
with the skin and in particular with the stratum corneum
(SC). It is well known that CD may interact with some
components of the skin, but contradictory results have been
reported so far [2]. For instance, Dimeb is known to extract
cholesterol and triglycerides from powdered hide and from
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rabbit skin in vitro, a process that may alter the barrier
function of the SC and eventually may lead to increased
drug absorption [3]. It is generally assumed that the SC
barrier is disrupted through intercellular lipid removal and
protein alteration. In such a case, particular attention should
be directed toward the possible irritation effects of CD on
the skin [4]. The lack of toxicological data hampers
pharmaceutical applications of CD [2].
The aim of this study was to compare the skin irritation
potential of the new DMPE-CD derivatives with that of
native CD (bCD and gCD) and CD derivatives currently
used for pharmaceutical applications including the ran-
domly methylated bCD (Rameb), the dimethylated bCD
(Dimeb), the trimethylated bCD (Trimeb) and the hydro-
xypropylated bCD and gCD (HP-bCD and HP-gCD). For
this purpose, the corneoxenometry bioassay was performed
on human SC.
Corneoxenometry, named after the terms corneocyte,
xenobiotic and metry, was designed for testing chemicals
biologically harmful to the SC [4–7]. It is a variant of
corneosurfametry initially developed to rate the aggressive-
ness of surfactants on human SC [5, 8]. The substrate used
for testing is normal human SC collected by skin surface
stripping (SSS) using cyanoacrylate adhesive and terephta-
late polymer sheets. The harvested material corresponding
to a uniform sheet of SC is submitted to the action of
xenobiotics ex vivo (immersion into a solution). Once the
contact time is over, samples are dried and stained with
basic fuchsin–toluidine blue dye solution (polychrome
multiple stain, PMS). Normal SC avidly binds anionic dyes
because corneocytes are covered by acidophilic, positively
charged loci. Once altered by a series of chemicals or other
threats, corneocytes exhibit distinct staining properties by
cationic dyes. One of the most convenient mixtures
associates basic fuchsin and toluidine blue which stain
selectively the altered stratum corneum. The interaction can
be explained by three complementary mechanisms:
† The treatment extracts lipids of corneocytes, increasing
the access of PMS to cell membrane proteins.
† The treatment denatures proteins of corneocytes
increasing the number of negative charges fixing PMS.
† The treatment is adsorbed on corneocytes forming a
bridge fixing PMS.
Whatever the hypothesis, quantifying the changes in the
colour of the stained CSSS was considered to be an indicator
of the amount of sites exposed on the surface of corneocytes
by xenobiotics eliciting removal of intercellular lipids and
denaturation of proteins [5].
Accurate colour expression depends on three primary
elements: hue (rainbow colours), corresponding to the
dominant wavelength, lightness (brightness) and saturation
(vividness). The continuum in colour hues is classically
pictured as a colour wheel clearly exhibiting the comp-
lementary hues (red-green, yellow-blue, …). In terms of
physics lightness represents the colour value, and saturation
is called chroma. A three-dimensional representation of
colours is obtained by the combination of the hue colour
wheel with a vertical axis of value and a horizontal axis of
chroma from the centre. Quantitative and repetitive
measurements are only reliable when objective measure-
ments are made. This can be achieved by reflectance
tristimulus Commission Internationale de l’Eclairage (CIE)
colorimetry. The CIELAB colour space system is now
widely used [9].
Value L* is expressed on a scale ranging from 0 for black
to 100 for white. Hue and chroma are expressed by
combining chromacities a* and b*. In the colour wheel
(Fig. 2), a* and b* indicate two orthogonal colour axes, with
a* being the red (þ100) and green (2100) axis and b* the
yellow (þ100)-blue (2100) axis. The positive section of
axis a* (red) and the positive section of axis b* (yellow) are
used to measure skin colours. Chroma C* is described by
the equation, C* ¼ ða* 2 þ b* 2Þ1=2 [9]. Corneoxenometry
data are expressed by the colorimetric index of mildness
(CIM) which corresponds to the difference between L* and
chroma C* values of each CSSS test sample. Previous
studies have shown decreased CIM values with increasing
irritancy of test products. Irritant products have CIM values
lower than 30; those that are very irritant have a CIM value
lower than 10 and even negative value. The CIM water
value (mildness reference) is around 64 while that of sodium
laurylsulfate, a reference irritating product, may be as low as
5–15 [8].
Fig. 1. Chemical structure of the phospholipidyl-cyclodextrin: DMPE-Dimeb and DMPE-Trimeb.
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Results obtained by corneoxenometry or corneosurfa-
metry show good correlations with those of other in vitro
tests and in vivo studies [6].
2. Material and methods
2.1. Materials
bCD was obtained from CNI (Neuilly-sur-Seine,
France), gCD, HP-gCD and Rameb were obtained from
Wacker Chemie GmbH (Munchen, Germany), Dimeb and
Trimeb were from Cyclolab (Budapest, Hungary) and HP-
bCD from Janssen Biotech (Olen, Belgium).
DMPE-Dimeb and DMPE-Trimeb were synthesized
following the method described by Moutard [10].
2.2. Experimental design
CSSS were harvested from the ventral forearms of five
healthy volunteers using a cyanoacrylate adhesive (Super-
glue 3, Loctite) and terephthalate polymer sheets (Melinex
O, ICI plastic division).
Samples were immersed into 5% (W/V) CD aqueous
solutions for 2 h. at room temperature (20 8C) in a closed
environment to prevent evaporation of the test products.
Due to its low aqueous solubility, bCD was tested at 1.5%
(W/V). Once the contact time was over, samples were
thoroughly rinsed under running tap water. After air-drying,
they were stained for 3 min by PMS. After removal of the
excess dye and abundant rinsing with water, the samples
were dried.
The resulting corneocyte alterations were quantified
using reflectance colorimetry. Samples were placed on a
white tile (Minolta reference plate) and a colour reflectance
meter (Chroma Meter CR 200, Minolta, Osaka, Japan) was
used to record luminancy L* and Chroma C*.
For each series of evaluations, medians and ranges of
CIM values were calculated. Statistical evaluations were
performed using the paired non-parametric Friedman test
followed by the Dunn’s paired test. A P-value lower than
0.05 was considered as reaching statistical significance.
3. Results and discussion
Corneoxenometry is a predictive bioassay testing the
compatibility of xenobiotics with the SC. Any disruption in
the lipid bilayers of the SC and any protein denaturation of
the corneocytes, a process that may reduce the barrier
function of the SC and may induce irritation, is revealed by
controlled colorimetric means. The effect of organic
solvents, penetration enhancers and barrier creams were
tested by corneoxenometry with relevant predictive value
[4,6,7]. In this study, the corneoxenometry suggested that all
tested CD are globally well tolerated by the skin because
CIM medians values were above the threshold value of 30
for skin mildness (Fig. 3). Overall, no significant differences
Fig. 2. Colour wheel in the plane of the a* and b* axis.
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were yielded between most CD. The two exceptions were
DMPE-Dimeb and to a lesser extent Dimeb, which
exhibited significantly lower CIM values than those of
most other CD. No significant difference was observed
between Dimeb and DMPE-Dimeb. However, the large
inter-individual CIM variability for DMPE-Dimeb predicts
that some individuals suffer from reduced compatibility
with this compound. Subjects complaining of sensitive skin
might be those reacting with the lowest CIM values [8].
The present corneoxenometry data are in line with results
suggesting that Dimeb extracts components of the skin
(cholesterol, triglyceride) [3]. They are also consistent with
the results obtained by DSC showing that Dimeb affected
the endothermic peak transition of isolated human SC
whereas no noticeable changes were observed for the SC
treated with HP-bCD. Other studies have shown that HP-
bCD had limited specificity for cholesterol and triglycerides
[3]. The present study suggests that the phospholipidyl-
Dimeb derivative also extracts components of the skin to the
same extent as Dimeb since their CIM values are similar.
This means that DMPE-Dimeb could retain full capacity to
include some xenobiotics, which is of considerable
importance for potential applications.
This study confirms that most of the tested CD are well
tolerated with a good safety profile following topical
application. However, a minority of individuals might feel
uncomfortable with DMPE-Dimeb.
In conclusion, all tested CD (bCD, gCD, Rameb,
Trimeb, DMPE-Trimeb, HP-bCD, HP-gCD, DMPE-
Dimeb and DMPE-Trimeb) appear to be well tolerated by
the skin. However Dimeb and DMPE-Dimeb are less mild
than the others. Dimeb and the new phospholipidyl-CD
derivative, DMPE-Dimeb could be used as a skin absorption
enhancer because the alteration of the SC may lead to
increased drug absorption.
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